Study analysis · OncoImmunology · 2018
Your platelets may be helping cancer cells hide from your immune system.
Platelets cut off 'danger signals' from cancer cells, making them invisible to natural killer cells and potentially helping cancer spread.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study is like a test tube experiment. Scientists mixed cells and platelets in a dish and saw that the platelets can strip off some molecules from the cancer cells, making it harder for immune cells to recognize them. But this was done in a lab, not in a living person, so we can't say for sure this happens in patients. It's a clue, not proof.
What’s the bottom line?
When cancer cells enter the blood, platelets stick to them and release enzymes that cut off special markers on the cancer cells that alert immune cells.
How strong is this study?
The experiment was well-designed with multiple cell types and careful controls. Scientists used several methods to check their results. However, because it's in a dish, we don't know if the same thing happens in the complex environment of a human body. So the study is trustworthy for what it shows in the dish, but we need more studies in animals or humans to know if it matters for health.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
19 / 100
- Randomizationnot randomized
- Blindingblinding unclear
- Control group+15/15
- Sample sizeno sample size reported
- Follow-upno follow-up reported
100 / 100
23 / 100
- P-values+15/15
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 56 / 100
Probability of being correct
Snapshots of a population at a single point in time, or descriptions of small groups. Can identify correlations and prevalence, but cannot determine cause and effect.
This design cannot establish causation — the findings describe an association, not a cause. In vitro study using cell lines; cannot establish causation in human biology. Demonstrates a possible mechanism under artificial conditions but lacks in vivo validation.
No Conflicts
No conflicts of interest identified
No conflicts of interest identified; all authors are from academic institutions and no funding sources are declared.
The provided text does not include a conflict of interest or funding statement. All affiliations are academic (German Cancer Research Center, University of Tuebingen, Goethe University). No industry funding or ties are evident.
Key takeaways
- 01
Platelets cut off MICA and MICB markers from cancer cells by about 50%, making them harder for NK cells to detect and kill.
- 02
Yes, it means platelets directly help cancer escape the immune system, which could promote metastasis.
Surprising findings
- Platelet-releasate alone (without platelet contact) reduces NK cell lysis by reducing NKG2D ligands on tumor cells.Previous theories suggested platelets physically shield tumor cells, but this shows soluble factors alone are sufficient to impair NK attack.
- ADAM10/17 levels on platelets are not linked to platelet activation state (resting vs. agonist-stimulated).Most platelet immune factors increase upon activation, but ADAM10/17 are constitutively present and released upon activation, not upregulated.
Practical takeaways
If you have cancer, discuss with your doctor whether anti-platelet drugs (like low-dose aspirin) might reduce metastasis risk, especially for cancers that spread via blood.
This is in vitro and ex vivo; no clinical trial data. Bleeding risk must be considered.
medium confidenceMonitor NK cell activity in patients with high platelet ADAM10/17 levels as a potential biomarker for metastasis.
Only studied in NSCLC; needs validation in other cancers and larger cohorts.
low confidenceWhy this study matters
Platelets: Double agents in cancer?
This study shows that when cancer cells enter the bloodstream, platelets coat them and remove MICA/MICB proteins from the surface using enzymes called ADAM10 and ADAM17. This reduces NK cell killing by 30-50% depending on the cell type.
Platelets are normally the good guys (clotting), but here they're revealed as unwitting accomplices in cancer immune evasion.
How platelets snip off danger signals
Platelets release ADAM10 and ADAM17, which cleave MICA and MICB from tumor cells. Even liquid released by platelets (releasate) alone can do this without direct contact, as shown by flow cytometry and ELISA.
This explains how even a brief encounter with platelets can permanently impair NK cell recognition of cancer cells.
Cancer patients have more aggressive platelet enzymes
Platelets from NSCLC patients have significantly higher levels of ADAM10 and ADAM17 compared to healthy donors (p<0.05), potentially making them better at helping cancer hide.
This is a measurable biomarker that could predict metastasis risk or guide anti-platelet therapies.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
When cancer cells enter the blood, platelets stick to them and release enzymes that cut off special markers on the cancer cells that alert immune cells.
Research results
Platelets cut off MICA and MICB markers from cancer cells by about 50%, making them harder for NK cells to detect and kill.
What this means - more context
Yes, it means platelets directly help cancer escape the immune system, which could promote metastasis.
To investigate how platelets reduce NKG2D ligand expression on tumor cells and impair NK cell cytotoxicity.
Platelets and platelet-releasate reduce surface NKG2D ligands (MICA/MICB) on tumor cells via ADAM10/17 shedding, impairing NKG2D-dependent NK cell lysis.
Methods Used
Co-culture of colon/breast cancer cell lines with platelets or releasate; flow cytometry, ELISA, chromium release assays; blocking ADAM10/17; patient platelet analysis.
Main Finding
Platelet-mediated shedding of NKG2D ligands via ADAM10/17 reduces NK cell lysis, with up to 30-50% reduction depending on cell line and E:T ratio.
Confidence Level
Moderate: robust in vitro data but lack of direct ADAM10/17 depletion and in vivo validation.
Study Flags
Red Flags
- •No direct ADAM10/17 depletion experiments
- •Limited to in vitro and ex vivo (patient platelets)
- •Potential confounding by other platelet factors
Surprising Findings
Platelet-releasate alone (without platelet contact) reduces NK cell lysis by reducing NKG2D ligands on tumor cells.
Previous theories suggested platelets physically shield tumor cells, but this shows soluble factors alone are sufficient to impair NK attack.
Practical Takeaways
If you have cancer, discuss with your doctor whether anti-platelet drugs (like low-dose aspirin) might reduce metastasis risk, especially for cancers that spread via blood.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 56 / 100
Probability of being correct
Snapshots of a population at a single point in time, or descriptions of small groups. Can identify correlations and prevalence, but cannot determine cause and effect.
In Vitro Cross-Sectional
Subject
Lower probability
on the GRADE evidence scale
This study is like a test tube experiment. Scientists mixed cells and platelets in a dish and saw that the platelets can strip off some molecules from the cancer cells, making it harder for immune cells to recognize them. But this was done in a lab, not in a living person, so we can't say for sure this happens in patients. It's a clue, not proof.
No conflicts of interest were detected in this study. No score impact.
Strengths
- Multiple complementary assays (FACS, ELISA, cytotoxicity, Western blot).
- Use of blocking antibodies and agonistic NKG2D antibody to confirm specificity.
- Controls for technical artifacts (e.g., platelet-coating interference with FACS).
Weaknesses
- In vitro model: lacks physiological relevance of blood flow, immune cell interactions, and tumor microenvironment.
- No direct loss-of-function experiments for ADAM10/17 (e.g., knockdown or inhibition).
- Small sample of patient platelets (n=24, single time point) with no functional data linking to NK evasion.
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
When cancer cells enter the blood, platelets stick to them and release enzymes that cut off special markers on the cancer cells that alert immune cells.
Research results
Platelets cut off MICA and MICB markers from cancer cells by about 50%, making them harder for NK cells to detect and kill.
What this means - more context
Yes, it means platelets directly help cancer escape the immune system, which could promote metastasis.
To investigate how platelets reduce NKG2D ligand expression on tumor cells and impair NK cell cytotoxicity.
Platelets and platelet-releasate reduce surface NKG2D ligands (MICA/MICB) on tumor cells via ADAM10/17 shedding, impairing NKG2D-dependent NK cell lysis.
Methods Used
Co-culture of colon/breast cancer cell lines with platelets or releasate; flow cytometry, ELISA, chromium release assays; blocking ADAM10/17; patient platelet analysis.
Main Finding
Platelet-mediated shedding of NKG2D ligands via ADAM10/17 reduces NK cell lysis, with up to 30-50% reduction depending on cell line and E:T ratio.
Confidence Level
Moderate: robust in vitro data but lack of direct ADAM10/17 depletion and in vivo validation.
Study Flags
Red Flags
- •No direct ADAM10/17 depletion experiments
- •Limited to in vitro and ex vivo (patient platelets)
- •Potential confounding by other platelet factors
Surprising Findings
Platelet-releasate alone (without platelet contact) reduces NK cell lysis by reducing NKG2D ligands on tumor cells.
Previous theories suggested platelets physically shield tumor cells, but this shows soluble factors alone are sufficient to impair NK attack.
Practical Takeaways
If you have cancer, discuss with your doctor whether anti-platelet drugs (like low-dose aspirin) might reduce metastasis risk, especially for cancers that spread via blood.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 56 / 100
Probability of being correct
Snapshots of a population at a single point in time, or descriptions of small groups. Can identify correlations and prevalence, but cannot determine cause and effect.
In Vitro Cross-Sectional
Subject
Lower probability
on the GRADE evidence scale
This study is like a test tube experiment. Scientists mixed cells and platelets in a dish and saw that the platelets can strip off some molecules from the cancer cells, making it harder for immune cells to recognize them. But this was done in a lab, not in a living person, so we can't say for sure this happens in patients. It's a clue, not proof.
No conflicts of interest were detected in this study. No score impact.
Strengths
- Multiple complementary assays (FACS, ELISA, cytotoxicity, Western blot).
- Use of blocking antibodies and agonistic NKG2D antibody to confirm specificity.
- Controls for technical artifacts (e.g., platelet-coating interference with FACS).
Weaknesses
- In vitro model: lacks physiological relevance of blood flow, immune cell interactions, and tumor microenvironment.
- No direct loss-of-function experiments for ADAM10/17 (e.g., knockdown or inhibition).
- Small sample of patient platelets (n=24, single time point) with no functional data linking to NK evasion.
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
The experiment was well-designed with multiple cell types and careful controls. Scientists used several methods to check their results. However, because it's in a dish, we don't know if the same thing happens in the complex environment of a human body. So the study is trustworthy for what it shows in the dish, but we need more studies in animals or humans to know if it matters for health.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
19 / 100
- Randomizationnot randomized
- Blindingblinding unclear
- Control group+15/15
- Sample sizeno sample size reported
- Follow-upno follow-up reported
100 / 100
23 / 100
- P-values+15/15
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 56 / 100
Probability of being correct
Snapshots of a population at a single point in time, or descriptions of small groups. Can identify correlations and prevalence, but cannot determine cause and effect.
This design cannot establish causation — the findings describe an association, not a cause. In vitro study using cell lines; cannot establish causation in human biology. Demonstrates a possible mechanism under artificial conditions but lacks in vivo validation.
No Conflicts
No conflicts of interest identified
No conflicts of interest identified; all authors are from academic institutions and no funding sources are declared.
The provided text does not include a conflict of interest or funding statement. All affiliations are academic (German Cancer Research Center, University of Tuebingen, Goethe University). No industry funding or ties are evident.
Standing
Who’s using this study?
The videos and claims on this site that lean on this study, and the researchers who wrote it.
1 video from Dr. William Wallace cite this study, drawing 1 claim from it.
- Indication only
Weak evidence — fewer than 20 studies, so treat this as a starting point, not a fact.
Evidence